Mikkel Wandahl Pedersen
Overview
Explore the profile of Mikkel Wandahl Pedersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuczkowska K, Bjerkan L, Stubsrud E, Husbyn H, Chellappa S, Hauge A, et al.
Sci Rep
. 2023 Nov;
13(1):18902.
PMID: 37919366
Throughout the COVID-19 pandemic, several variants of concern (VoC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have evolved, affecting the efficacy of the approved COVID-19 vaccines. To address...
2.
Poulsen T, Grandal M, Skartved N, Hald R, Alifrangis L, Koefoed K, et al.
Clin Cancer Res
. 2017 Jul;
23(19):5923-5935.
PMID: 28679766
Activation of the receptor tyrosine kinase MET is associated with poor clinical outcome in certain cancers. To target MET more effectively, we developed an antagonistic antibody mixture, Sym015, consisting of...
3.
Kjaer I, Lindsted T, Frohlich C, Olsen J, Horak I, Kragh M, et al.
Mol Cancer Ther
. 2016 May;
15(7):1614-26.
PMID: 27196767
Squamous cell carcinomas (SCC) arising in upper parts of the aerodigestive tract are among the leading causes of death worldwide. EGFR has been found to play an essential role in...
4.
Koefoed K, Steinaa L, Soderberg J, Kjaer I, Jacobsen H, Meijer P, et al.
MAbs
. 2011 Nov;
3(6):584-95.
PMID: 22123060
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical...
5.
Skartved N, Jacobsen H, Pedersen M, Jensen P, Sen J, Jorgensen T, et al.
Clin Cancer Res
. 2011 Aug;
17(18):5962-72.
PMID: 21825041
Purpose: Sym004 is a novel therapeutic antibody mixture product comprising two unmarketed monoclonal antibodies (mAb) targeting the epidermal growth factor receptor (EGFR). In previous preclinical proof-of-concept studies, Sym004 was shown...
6.
Pedersen M, Jacobsen H, Koefoed K, Hey A, Pyke C, Haurum J, et al.
Cancer Res
. 2010 Jan;
70(2):588-97.
PMID: 20068188
Epidermal growth factor receptor (EGFR) is a validated therapeutic target in cancer and EGFR antagonists with greater effectiveness than existing clinical agents remain of interest. Here, we report a novel...
7.
Andersen P, Pedersen M, Woetmann A, Villingshoj M, Stockhausen M, Odum N, et al.
Int J Cancer
. 2007 Oct;
122(2):342-9.
PMID: 17918184
Recently, we reported that epidermal growth factor receptor (EGFR) induce expression of a module of genes known to be inducible by interferons and particularly interferon-gamma. Here we show that the...
8.
Larsen A, Pedersen M, Stockhausen M, Grandal M, van Deurs B, Poulsen H
Mol Cancer Res
. 2007 Mar;
5(3):283-93.
PMID: 17374733
EphA2 overexpression has been reported in many cancers and is believed to play an important role in tumor metastasis and angiogenesis. We show that the activated epidermal growth factor receptor...
9.
Pedersen M, Poulsen H
Ugeskr Laeger
. 2006 Jul;
168(24):2354-61.
PMID: 16822420
The epidermal growth factor receptor (EGFR) plays an important role in the regulation of normal cell proliferation, differentiation and survival. For this reason EGFR status is often altered in a...
10.
Damstrup L, Pedersen M, Bastholm L, Elling F, Poulsen H
Int J Cancer
. 2002 Jan;
97(1):7-14.
PMID: 11774237
In the present study we transfected the epidermal growth factor receptor (EGFR)-negative small cell lung cancer cell line, GLC3, with the type III EGFR mutation (EGFRvIII). The EGFRvIII protein could...